Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:42 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,419 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Active capsule Clear all
Withdrawn Phase 2 Interventional

Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence

NCT03566290
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
GTx-024
Drug
Lead sponsor
GTx
Industry
Eligibility
18 Years to 80 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
46
States / cities
Homewood, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Nov 3, 2026, 11:42 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Cortisol Regulation in Polycystic Ovary Syndrome (PCOS)

NCT00694759
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
pioglitazone, metformin, placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Nov 3, 2026, 11:42 AM EST
Completed Not applicable Interventional

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

NCT07189442
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
Interventions
L-theanine and paraxanthine, Placebo
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements

NCT06258265
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-279, TAK-279 Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Nov 3, 2026, 11:42 AM EST
Terminated Phase 3 Interventional Results available

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium/Salmeterol, Salmeterol, Placebo, Tiotropium
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
16
States / cities
Anniston, Alabama • Mobile, Alabama • Clearwater, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Nutraceutical Effects on Long-Term Memory

NCT01963767
View directory record Official record
Conditions
Aging
Interventions
NT-020, Placebo
Drug · Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
65 Years to 85 Years
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 4, 2014 · Synced Nov 3, 2026, 11:42 AM EST
Active, not recruiting Phase 3 Interventional

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744
View directory record Official record
Conditions
Follicular Lymphoma (FL)
Interventions
Epcoritamab, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
1,095 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
58
States / cities
Fresno, California • San Diego, California • Santa Barbara, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

NCT01854645
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
GFF MDI, GP MDI, FF MDI, Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
2,103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Nov 3, 2026, 11:42 AM EST
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III

NCT02710331
View directory record Official record
Conditions
Cannabis, Alcohol Effect, Driving Under the Influence of Alcohol and Other Drugs
Interventions
Active Dronabinol, Placebo, Active Ethanol
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Results available

Neurobiology of Bulimia Nervosa

NCT04225221
View directory record Official record
Conditions
Bulimia Nervosa
Interventions
Estradiol, Micronized progesterone, Leuprolide Acetate, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Nov 3, 2026, 11:42 AM EST
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006

NCT01463098
View directory record Official record
Conditions
Insomnia
Interventions
E2006 1.0 mg, E2006 2.5 mg, E2006 5.0 mg, E2006 10.0 mg, E2006 25.0 mg, E2006 50.0 mg, E2006 100 mg, E2006 200 mg, Zolpidem 10 mg, E2006 Matched Placebo or Zolpidem Matched Placebo, E2006 Matched Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 4 Interventional Results available

Prevention of Persistent Opioid Use in Mothers

NCT03472521
View directory record Official record
Conditions
Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 3 Interventional Results available

A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00361335
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Golimumab, Methotrexate, Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
20
States / cities
Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Results available

Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)

NCT01888874
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GLPG0634, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 3, 2026, 11:42 AM EST
Terminated Phase 3 Interventional Results available

Pediatric Chronic Kidney Disease Safety and Efficacy

NCT01277510
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
Interventions
cinacalcet capsule, placebo, Standard of Care
Drug
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional

Immune Mechanisms of Vitamin D to Reduce Chronic Pain After Burn

NCT05619289
View directory record Official record
Conditions
Burn Injury, Chronic Pain
Interventions
Ergocalciferol, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

NCT05283720
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
18
States / cities
Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Results available

The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity

NCT03364335
View directory record Official record
Conditions
Obesity
Interventions
Leu Sil 1.0mg, Leu Sil 4.0mg, Leu Met Sil 1.0mg, Leu Met Sil 4.0mg, Placebo
Drug
Lead sponsor
NuSirt Biopharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
15
States / cities
Mobile, Alabama • Montclair, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of LCI699 Compared to Placebo in Participants With Resistant Hypertension

NCT00817635
View directory record Official record
Conditions
Hypertension
Interventions
LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
37
States / cities
Mobile, Alabama • Sierra Vista, Arizona • Buena Park, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional

Study of the Safety and Efficacy of RGH-896 in Patients With Diabetic Peripheral Neuropathic Pain

NCT00838799
View directory record Official record
Conditions
Diabetic Peripheral Neuropathic Pain
Interventions
RGH-896, pregabalin, placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
54
States / cities
Birmingham, Alabama • Mesa, Arizona • Tempe, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Fasting Conditions

NCT00864058
View directory record Official record
Conditions
Healthy
Interventions
Gabapentin 400 mg capsules, NEURONTIN® 400 mg capsules
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2010 · Synced Nov 3, 2026, 11:42 AM EST
Completed Phase 2 Interventional Results available

The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease

NCT00715117
View directory record Official record
Conditions
Crohn's Disease
Interventions
Naltrexone, Placebo, sugar pill
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Nov 3, 2026, 11:42 AM EST
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2021 · Synced Nov 3, 2026, 11:42 AM EST